Nitto Denko Corporation, an Osaka, Japan-based manufacturer of industrial and life science products, will invest approximately JPY 25 billion ($255 million) in its Milford, Massachusetts subsidiary, Nitto Denko Avecia, and other business to increase oligonucleotide manufacturing capacity and related capabilities in process and analytical development.

Nitto Denko Avecia is expanding process and analytical development capabilities for oligonucleotides. The process development building is scheduled to start operations in 2021. It also will establish a new building and production line for commercial manufacturing of drug substances. The commercial manufacturing building and production line are scheduled to start operations in early 2023.

Future plans include another JPY 25-billion ($255-million) investment to further increase the supply capacity of the polymer support used for oligonucleotide therapeutic manufacturing and expand the production line of oligonucleotide therapeutics for early clinical scales.

Source: Nitto Denko Corporation